Non-pharmacologial, Non-invassive Intervention Before Cardiac Surgery: a Randomized Controlled Trial
Launched by CHINA NATIONAL CENTER FOR CARDIOVASCULAR DISEASES · Jan 19, 2025
Trial Information
Current as of July 24, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at two techniques—remote ischemic preconditioning and transcranial electrical stimulation—to see if they can help prevent neurological complications that sometimes happen during heart surgery. These complications can lead to serious problems like disability or even death, so the researchers want to find out if these methods are effective and safe for patients who are at high risk. Participants in the study will either receive these treatments or a placebo (a "dummy" treatment) twice a day for three days before their surgery.
To be eligible for this trial, participants need to be between 18 and 80 years old and scheduled for elective heart surgery. They should also have a history of heart disease and be considered at high risk for neurological issues after surgery, which might include having had a previous stroke or certain artery conditions. After the surgery, participants will take part in follow-up assessments to monitor their recovery. The trial is not yet recruiting, but it’s an important step toward improving safety and outcomes for patients undergoing cardiac procedures.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Age range: 18-80 years old;
- • 2. Surgical patients with heart disease;
- • 3. Elective surgery;
- • 4. Patients identified as high-risk for postoperative neurological complications; Previous stroke history; Moderate to severe stenosis of the head and neck arteries was evaluated;
- • 5. Be able to understand and comply with the requirements of clinical trial protocols, and voluntarily sign informed consent forms.
- Exclusion Criteria:
- • -
About China National Center For Cardiovascular Diseases
The China National Center for Cardiovascular Diseases (NCCD) is a leading research and clinical trial sponsor dedicated to advancing cardiovascular health in China and globally. As a prominent institution, NCCD focuses on innovative research, clinical management, and education in cardiovascular medicine. The center plays a crucial role in conducting rigorous clinical trials aimed at developing new therapies and improving patient outcomes for cardiovascular diseases. Through collaboration with national and international partners, NCCD is committed to enhancing the understanding of cardiovascular conditions and translating research findings into practical applications for improved healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, Beijing, China
Patients applied
Trial Officials
Shujuan Li, M.D.
Study Director
Chinese Academy of Medical Sciences, Fuwai Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported